Opendata, web and dolomites

Super-Vaccine SIGNED

Exploring the potential applications of live viral vaccine encoded small-hairpin-RNAs in improving both vaccine safety and efficacy through RNA-interference and stimulation of the innate immune system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Super-Vaccine project word cloud

Explore the words cloud of the Super-Vaccine project. It provides you a very rough idea of what is the project "Super-Vaccine" about.

strain    recombine    strategic    live    followed    progression    strategy    propagation    shrnas    perspective    circulating    inducers    intrinsic    rnas    occurrences    lower    launched    security    functioning    mind    express    disease    efficacy    modifying    beneficial    reduce    ultimately    vaccination    instrumental    tomorrow    trials    market    immune    herpesvirus    stimulation    viral    wt    virus    small    potency    food    innate    desirable    exclusively    outline    wild    expression    harmony    appropriately    efforts    meet    rna    genetically    interference    programs    safety    recombination    capacity    viruses    attenuated    ongoing    rnai    societal    global    interferon    basis    spread    roadmap    replication    hairpin    explored    2016    cyprinid    innovation    priorities    strains    doses    vitro    feasible    interventions    potent    levels    inhibit    explore    vaccines    vaccine    reducing    manufacturing    economically    designed    vivo    ifn    primary    healthcare   

Project "Super-Vaccine" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE LIEGE 

Organization address
address: PLACE DU 20 AOUT 7
city: LIEGE
postcode: 4000
website: www.ulg.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2018
 Duration (year-month-day) from 2018-09-19   to  2020-09-18

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE LIEGE BE (LIEGE) coordinator 160˙800.00

Map

 Project objective

Live vaccines represent one of the most important and effective interventions against the spread of viral disease. As such, they are instrumental in addressing ongoing societal challenges in areas such as healthcare and global food security. However, their capacity to genetically recombine with wild type (WT) viruses circulating in the field remains a primary safety concern. Modifying live vaccine strains to reduce such occurrences would be highly desirable from a safety perspective. Also efforts to enhance the intrinsic potency of vaccine strains would be very beneficial. This would facilitate the use of much lower doses, while reducing the manufacturing resources required to meet market needs and the cost of vaccination programs.

With this in mind, this project will explore a novel strategy to improve both the safety and efficacy of live viral vaccine strains by modifying them to express small-hairpin-RNAs (shRNAs), which can be designed to:

i) Exclusively inhibit WT virus replication/propagation via RNA-interference (RNAi), thus reducing the levels of WT available for recombination with vaccine strains during vaccination i.e. improving safety

ii) Increase live vaccine strain stimulation of the innate immune system by functioning as potent inducers of Type-1 Interferon (IFN-I) expression during vaccination i.e. enhancing efficacy

This novel strategy will be explored by modifying an existing attenuated Cyprinid herpesvirus-3 vaccine strain to express appropriately designed shRNAs, followed by an assessment of their impact on both WT virus replication and IFN-I expression in-vitro, providing a basis for future progression to in-vivo trials.

Ultimately, if feasible, this novel vaccine design strategy may be applied in the control of many economically important viruses. Also elements of this project are in harmony with the “Strategic European Roadmap for the Vaccines of Tomorrow” launched in 2016 to outline specific EU priorities in future vaccine innovation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPER-VACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPER-VACCINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

GW (2019)

Analysing the heavy element factories of the Universe : photometric and spectroscopic sample study of kilonovae

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More